← Leaderboards
Randolph J. Noelle
University Of Minnesota
$36,126,144
Attributed
$43,453,622
Total exposure
33
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$43,703,867 · 34
By mechanism
R01$33,639,152 · 16
R37$3,640,301 · 1
R42$1,949,257 · 1
R44$998,002 · 1
R41$890,914 · 2
S10$670,150 · 5
Top collaborators
- Mary J Turk5 shared
- Edward John Usherwood5 shared
- Bruce R. Blazar4 shared
- Rodwell Mabaera4 shared
- Matthew F. Mackey1 shared
- Michael Rosenzweig1 shared
- Jay L Rothstein1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Melanie Lynn Graham$4,351,919
- Christopher Burlak$1,535,919
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoT-LymphocyteImmuneImmunityMediatingCytokinePreventBaseProductionImmune ResponseInflammatorySignal TransductionMolecularAntigensAutoimmunityReceptorRegulationIn VitroAgonistPathway InteractionsLaboratory MouseMalignant NeoplasmsInflammation
Grant awards (118)
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$656,304
R01 · FY2024 · HL
VISTA is a negative checkpoint regulator of innate immunity$796,349
R01 · FY2023 · AI · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$669,698
R01 · FY2023 · HL
VISTA is a negative checkpoint regulator of innate immunity$801,269
R01 · FY2022 · AI · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$662,404
R01 · FY2022 · HL
VISTA is a negative checkpoint regulator of innate immunity$804,549
R01 · FY2021 · AI · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$675,176
R01 · FY2021 · HL
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors$570,047
R01 · FY2021 · CA · contact PI
Negative regulation of Lupus by the VISTA Pathway$342,271
R01 · FY2021 · AR · contact PI
VISTA is a negative checkpoint regulator of innate immunity$820,549
R01 · FY2020 · AI · contact PI
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors$570,047
R01 · FY2020 · CA · contact PI
Negative regulation of Lupus by the VISTA Pathway$352,858
R01 · FY2020 · AR · contact PI
Retinoic acid in gut immune homestatis and infection$594,606
R01 · FY2019 · AI · contact PI
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors$552,945
R01 · FY2019 · CA · contact PI
Negative regulation of Lupus by the VISTA Pathway$352,858
R01 · FY2019 · AR · contact PI
Retinoic acid in gut immune homestatis and infection$594,606
R01 · FY2018 · AI · contact PI
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors$570,047
R01 · FY2018 · CA · contact PI
Negative regulation of Lupus by the VISTA Pathway$352,858
R01 · FY2018 · AR · contact PI
Retinoic acid in gut immune homestatis and infection$594,606
R01 · FY2017 · AI
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors$570,047
R01 · FY2017 · CA · contact PI
Negative regulation of Lupus by the VISTA Pathway$366,498
R01 · FY2017 · AR · contact PI
Retinoic acid in gut immune homestatis and infection$594,606
R01 · FY2016 · AI
VISTA, a novel regulator of immunity and autoimmunity$578,486
R01 · FY2016 · AI · contact PI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$954,097
R42 · FY2015 · AI
Retinoic acid in gut immune homestatis and infection$609,843
R01 · FY2015 · AI
VISTA, a novel regulator of immunity and autoimmunity$578,486
R01 · FY2015 · AI · contact PI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$995,160
R42 · FY2014 · AI
VISTA, a novel regulator of immunity and autoimmunity$578,486
R01 · FY2014 · AI · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$124,350
P30 · FY2014 · CA · contact PI
Safe and effective anti CD154 antibodies for therapeutic intervention$998,002
R44 · FY2013 · AI
VISTA, a novel regulator of immunity and autoimmunity$527,943
R01 · FY2013 · AI · contact PI
Vitamin A and acquired immune privilege$480,451
R01 · FY2013 · AT · contact PI
Cognate Activation of B-Lymphocytes$368,288
R37 · FY2013 · AI · contact PI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$300,000
R41 · FY2013 · AI · contact PI
Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention$290,914
R41 · FY2013 · AI · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$59,184
P30 · FY2013 · CA · contact PI
VISTA, a novel regulator of immunity and autoimmunity$537,398
R01 · FY2012 · AI · contact PI
Vitamin A and acquired immune privilege$484,386
R01 · FY2012 · AT · contact PI
Cognate Activation of B-Lymphocytes$391,795
R37 · FY2012 · AI · contact PI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$300,000
R41 · FY2012 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$136,045
R01 · FY2012 · CA · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$64,877
P30 · FY2012 · CA · contact PI
Vitamin A and acquired immune privilege$481,525
R01 · FY2011 · AT · contact PI
Cognate Activation of B-Lymphocytes$391,795
R37 · FY2011 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$294,696
R01 · FY2011 · CA · contact PI
The Th17-IL-9 mast cell axis in inflammatory disease$117,315
R21 · FY2011 · AI · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$66,500
P30 · FY2011 · CA · contact PI
Vitamin A and acquired immune privilege$542,908
R01 · FY2010 · AT · contact PI
Cognate Activation of B-Lymphocytes$362,772
R37 · FY2010 · AI · contact PI
Effector Mechanisms in Graft Tolerance$345,560
R01 · FY2010 · AI · contact PI
The Th17-IL-9 mast cell axis in inflammatory disease$316,000
R21 · FY2010 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$303,810
R01 · FY2010 · CA · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$78,003
P30 · FY2010 · CA · contact PI
Vitamin A and acquired immune privilege$521,816
R01 · FY2009 · AT · contact PI
Cognate Activation of B-Lymphocytes$399,750
R37 · FY2009 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$391,469
R01 · FY2009 · CA · contact PI
Effector Mechanisms in Graft Tolerance$380,783
R01 · FY2009 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$303,810
R01 · FY2009 · CA · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$286,422
R01 · FY2009 · CA · contact PI
Effector Mechanisms in Graft Tolerance$154,116
R01 · FY2009 · AI · contact PI
COBRE CORE D: INFORMATICS SUPPORT CORE$119,916
P20 · FY2009 · RR · contact PI
IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM$75,460
P30 · FY2009 · CA · contact PI
Effector Mechanisms in Graft Tolerance$380,783
R01 · FY2008 · AI · contact PI
Cognate Activation of B-Lymphocytes$330,675
R37 · FY2008 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$303,810
R01 · FY2008 · CA · contact PI
BCMA: Controlling the survival of differentiated B cells$248,647
R01 · FY2008 · CA · contact PI
COBRE CORE D: INFORMATICS SUPPORT CORE$117,519
P20 · FY2008 · RR · contact PI
Effector Mechanisms in Graft Tolerance$388,157
R01 · FY2007 · AI · contact PI
Cognate Activation of B-Lymphocytes$337,079
R37 · FY2007 · AI · contact PI
Synergy of the innate and acquired immune responses in tumor immunology$303,810
R01 · FY2007 · CA · contact PI
Regulation of Dendritic Cells and Cell Mediated Immunity by TNF family members$300,000
R01 · FY2007 · CA · contact PI
BCMA: Controlling the survival of differentiated B cells$248,647
R01 · FY2007 · CA · contact PI
COBRE CORE D: INFORMATICS SUPPORT CORE$116,443
P20 · FY2007 · RR · contact PI
Effector Mechanisms in Graft Tolerance$399,750
R01 · FY2006 · AI · contact PI
Cognate Activation of B-Lymphocytes$347,147
R37 · FY2006 · AI · contact PI
Regulation of DCs and CMIby TNF family members$308,960
R01 · FY2006 · CA · contact PI
Mechanisms of CD40 signaling in B lympocytes in vivo$308,574
R01 · FY2006 · AI · contact PI
BCMA: Controlling the survival of differentiated B cells$256,073
R01 · FY2006 · CA · contact PI
Purchase of a Xenogen's IVIS Imaging System 200 Workstation$250,245
S10 · FY2006 · RR · contact PI
PURCHASE OF A XENOGEN'S IVIS IMAGING SYSTEM 200 WORKSTATION: CANCER$125,122
S10 · FY2006 · RR · contact PI
PURCHASE OF A XENOGEN'S IVIS IMAGING SYSTEM 200 WORKSTATION: INFECTIOUS DISEASE$87,586
S10 · FY2006 · RR · contact PI
PURCHASE OF A XENOGEN'S IVIS IMAGING SYSTEM 200 WORKSTATION$37,537
S10 · FY2006 · RR · contact PI
CNS-RESTRICTED APC FUNCTION IN EAE$397,500
R01 · FY2005 · AI
TNF FAMILY MEMBERS GOVERN CD4 AND CD8 RESPONSES IN GVHD$357,750
R01 · FY2005 · AI
Cognate Activation of B-Lymphocytes$355,500
R37 · FY2005 · AI
Regulation of DCs and CMIby TNF family members$316,395
R01 · FY2005 · CA
Mechanisms of CD40 signaling in B lympocytes in vivo$316,000
R01 · FY2005 · AI
BCMA: Controlling the survival of differentiated B cells$262,236
R01 · FY2005 · CA
CNS-RESTRICTED APC FUNCTION IN EAE$397,500
R01 · FY2004 · AI
TNF FAMILY MEMBERS GOVERN CD4 AND CD8 RESPONSES IN GVHD$357,750
R01 · FY2004 · AI
Cognate Activation of B-Lymphocytes$355,500
R37 · FY2004 · AI
Regulation of DCs and CMIby TNF family members$316,395
R01 · FY2004 · CA
Mechanisms of CD40 signaling in B lympocytes in vivo$316,000
R01 · FY2004 · AI
BCMA: Controlling the survival of differentiated B cells$261,416
R01 · FY2004 · CA
CNS-RESTRICTED APC FUNCTION IN EAE$397,500
R01 · FY2003 · AI
TNF FAMILY MEMBERS GOVERN CD4 AND CD8 RESPONSES IN GVHD$357,750
R01 · FY2003 · AI
COGNATE ACTIVATION OF B LYMPHOCYTES$322,818
R01 · FY2003 · AI
Regulation of DCs and CMI by TNF family members$316,395
R01 · FY2003 · CA
Mechanisms of CD40 signaling in B lympocytes in vivo$316,000
R01 · FY2003 · AI
CNS-RESTRICTED APC FUNCTION IN EAE$571,300
R01 · FY2002 · AI
TNF FAMILY MEMBERS GOVERN CD4 AND CD8 RESPONSES IN GVHD$357,750
R01 · FY2002 · AI
Mechanisms of CD40 signaling in B lympocytes in vivo$316,083
R01 · FY2002 · AI
COGNATE ACTIVATION OF B LYMPHOCYTES$313,416
R01 · FY2002 · AI
CD40 REGULATES THE RESPONSE TO TRANSPLANTATION ANTIGENS$180,000
P01 · FY2002 · DK
Affimetrix High Density Workstation$169,660
S10 · FY2002 · RR
Core--Technical Support$0
P01 · FY2002 · AI
CNS-RESTRICTED APC FUNCTION IN EAE$377,625
R01 · FY2001 · AI
TNF FAMILY MEMBERS GOVERN CD4 AND CD8 RESPONSES IN GVHD$357,750
R01 · FY2001 · AI
COGNATE ACTIVATION OF B LYMPHOCYTES$304,288
R01 · FY2001 · AI
CD40 AND ENHANCED TUMOR IMMUNITY$239,831
R01 · FY2001 · CA
ASSEMBLY/REGULATION OF CD40 RECEPTOR COMPLEX IN B CELLS$219,158
R01 · FY2001 · AI
CD40 REGULATES THE RESPONSE TO TRANSPLANTATION ANTIGENS$180,000
P01 · FY2001 · DK
CORE--TECHNICAL SUPPORT FACILITY$0
P01 · FY2001 · AI
COGNATE ACTIVATION OF B LYMPHOCYTES$295,425
R01 · FY2000 · AI
CD40 AND ENHANCED TUMOR IMMUNITY$233,498
R01 · FY2000 · CA
ASSEMBLY/REGULATION OF CD40 RECEPTOR COMPLEX IN B CELLS$212,775
R01 · FY2000 · AI
CORE--TECHNICAL SUPPORT FACILITY$153,221
P01 · FY2000 · AI
CD40 REGULATES THE RESPONSE TO TRANSPLANTATION ANTIGENS$147,303
P01 · FY2000 · DK